These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 21190246)
1. Nanogel-based scaffold delivery of prostaglandin E(2) receptor-specific agonist in combination with a low dose of growth factor heals critical-size bone defects in mice. Kamolratanakul P; Hayata T; Ezura Y; Kawamata A; Hayashi C; Yamamoto Y; Hemmi H; Nagao M; Hanyu R; Notomi T; Nakamoto T; Amagasa T; Akiyoshi K; Noda M Arthritis Rheum; 2011 Apr; 63(4):1021-33. PubMed ID: 21190246 [TBL] [Abstract][Full Text] [Related]
2. The prostaglandin E(2) system: a toolbox for skeletal repair? Gelse K; Beyer C Arthritis Rheum; 2011 Apr; 63(4):871-3. PubMed ID: 21190302 [No Abstract] [Full Text] [Related]
3. Osteoblastic bone formation is induced by using nanogel-crosslinking hydrogel as novel scaffold for bone growth factor. Hayashi C; Hasegawa U; Saita Y; Hemmi H; Hayata T; Nakashima K; Ezura Y; Amagasa T; Akiyoshi K; Noda M J Cell Physiol; 2009 Jul; 220(1):1-7. PubMed ID: 19301257 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Toyoda H; Terai H; Sasaoka R; Oda K; Takaoka K Bone; 2005 Oct; 37(4):555-62. PubMed ID: 16027058 [TBL] [Abstract][Full Text] [Related]
6. Enhanced regeneration of the ligament-bone interface using a poly(L-lactide-co-ε-caprolactone) scaffold with local delivery of cells/BMP-2 using a heparin-based hydrogel. Lee J; Choi WI; Tae G; Kim YH; Kang SS; Kim SE; Kim SH; Jung Y; Kim SH Acta Biomater; 2011 Jan; 7(1):244-57. PubMed ID: 20801240 [TBL] [Abstract][Full Text] [Related]
7. Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo. Zhou H; Qian J; Wang J; Yao W; Liu C; Chen J; Cao X Biomaterials; 2009 Mar; 30(9):1715-24. PubMed ID: 19131102 [TBL] [Abstract][Full Text] [Related]
8. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Namikawa T; Terai H; Hoshino M; Kato M; Toyoda H; Yano K; Nakamura H; Takaoka K Spine (Phila Pa 1976); 2007 Oct; 32(21):2294-9. PubMed ID: 17906568 [TBL] [Abstract][Full Text] [Related]
9. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Huang Z; Ren PG; Ma T; Smith RL; Goodman SB Cytokine; 2010 Sep; 51(3):305-10. PubMed ID: 20580248 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of rhBMP-2 and natural latex as potential osteogenic proteins in critical size defects by histomorphometric methods. Issa JP; Defino HL; Netto JC; Volpon JB; Regalo SC; Iyomasa MM; Siéssere S; Tiossi R Anat Rec (Hoboken); 2010 May; 293(5):794-801. PubMed ID: 20225196 [TBL] [Abstract][Full Text] [Related]
12. Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment. Jiang GL; Im WB; Donde Y; Wheeler LA J Pharmacol Exp Ther; 2010 Dec; 335(3):546-52. PubMed ID: 20833794 [TBL] [Abstract][Full Text] [Related]
13. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Miguel BS; Ghayor C; Ehrbar M; Jung RE; Zwahlen RA; Hortschansky P; Schmoekel HG; Weber FE Tissue Eng Part A; 2009 Oct; 15(10):2955-63. PubMed ID: 19320543 [TBL] [Abstract][Full Text] [Related]
14. Growth factors and bone regeneration. Implications of barrier membranes. Zellin G Swed Dent J Suppl; 1998; 129():7-65. PubMed ID: 9672999 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. La WG; Kang SW; Yang HS; Bhang SH; Lee SH; Park JH; Kim BS Artif Organs; 2010 Dec; 34(12):1150-3. PubMed ID: 20545667 [TBL] [Abstract][Full Text] [Related]
16. Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Basmanav FB; Kose GT; Hasirci V Biomaterials; 2008 Nov; 29(31):4195-204. PubMed ID: 18691753 [TBL] [Abstract][Full Text] [Related]
17. The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation. Kanczler JM; Ginty PJ; White L; Clarke NM; Howdle SM; Shakesheff KM; Oreffo RO Biomaterials; 2010 Feb; 31(6):1242-50. PubMed ID: 19926128 [TBL] [Abstract][Full Text] [Related]
18. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Minamizaki T; Yoshiko Y; Kozai K; Aubin JE; Maeda N Bone; 2009 Jun; 44(6):1177-85. PubMed ID: 19233324 [TBL] [Abstract][Full Text] [Related]
19. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Hagino H; Kuraoka M; Kameyama Y; Okano T; Teshima R Bone; 2005 Mar; 36(3):444-53. PubMed ID: 15777678 [TBL] [Abstract][Full Text] [Related]